Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and Un

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and Un

Item

http://www.wikidata.org/entity/Q34048411

Q34048411

about

Emerging molecularly targeted therapies in castration refractory prostate cancer Epigenetic treatment of solid tumours: a review of clinical trials Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy Epigenetic modulators as therapeutic targets in prostate cancer Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy.Exploiting Epigenetic Alterations in Prostate Cancer.Molecular pathways: targeting ETS gene fusions in cancer.Current limitations and future opportunities for epigenetic therapies.Cancer Epigenetics: Mechanisms and Crosstalk of a HDAC Inhibitor, Vorinostat Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.The role of epithelial plasticity in prostate cancer dissemination and treatment resistance Small-molecular modulators of cancer-associated epigenetic mechanisms.Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts.Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer The biology of castration-resistant prostate cancer Augmenting antitumor immune responses with epigenetic modifying agents.Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer Epigenetics in prostate cancer.Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.Novel therapies for the treatment of advanced prostate cancer.Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management.HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies Translational and clinical implications of the genetic landscape of prostate cancer.Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors.KAT5 and KAT6B are in positive regulation on cell proliferation of prostate cancer through PI3K-AKT signaling.Manipulating the epigenome for the treatment of urological malignancies.Epigenetic therapy in urologic cancers: an update on clinical trials.Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration.Horizon scanning for novel therapeutics for the treatment of prostate cancer.Future directions in castrate-resistant prostate cancer therapy.Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.The changing therapeutic landscape of castration-resistant prostate cancer.Promises and challenges of anticancer drugs that target the epigenome.Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).

P2860

Q21284745-4F97AD86-EC51-4191-90AE-39C802D592E1 Q26773803-4D3D86F4-315F-4F69-9330-2319D6F2664A Q26775761-2763166F-AFEE-48F4-AF45-C1921E34277D Q27851813-3217DCD6-B71A-4DC7-91AE-7108E48C9B27 Q28071912-43E66C6D-0B66-433C-A252-5F7A245D038D Q28743074-9376F971-80B4-41A1-8460-6013624B047C Q33408846-8A5C4F2C-8972-45B6-A694-CE3A688012B4 Q33714950-B7978953-1E61-48F3-B720-3D0D3EFF5CA5 Q33755160-CA2CD1A4-AD8A-40DD-965B-CBDB88869887 Q34135434-E97C4060-E633-4365-99EC-2E3D5C09C052 Q34195077-982FA99B-AD74-4A05-B48D-DFD7DC800471 Q34213967-35B8D06B-FF35-4369-B41E-BF7BCA077B8C Q34416994-B95C1309-E64F-4719-9653-4F9865D1E7D4 Q34488424-6EF9529E-CFBD-4C12-9C74-06C9E1031130 Q34505037-3A7F6036-4AAF-47AB-9EF1-500D284FAC4C Q34628002-80AD221F-C997-4782-AD3A-107EAE6720C7 Q34810920-4DACFBE4-C78E-4E8D-9A52-C58B579542B7 Q34998552-98FB9932-8B79-460B-94E9-81F4AD389601 Q35039889-EDA2E9C9-13DF-4CAF-84BF-1BEC94DF675F Q35048054-DFE1DD0D-F897-4B38-9965-2B75B2ED3C56 Q35079955-FD4FC141-8A10-44FF-B461-FFB800390B55 Q35608952-DF3DC432-D504-40D0-A966-50D05DA5059F Q35939690-490B3AE7-6466-4FF0-AA71-A626B9EC8FE9 Q36665708-34C6F08E-AD88-4C76-9434-A36BFD52F098 Q36738463-3700C5A5-1D03-4D0A-A2A5-15F423CE4FCA Q36978594-C2CBA043-918C-48D1-8EF8-E7B1265174F7 Q37226511-1271AF82-8CC0-4E7A-96E9-38AB77097792 Q37270512-B618AF04-952C-49C2-A6EE-CC2E3B4A6051 Q37332601-C4EC87C1-A99C-4371-BBEE-550ACB4C11B3 Q37349488-EED9D7A9-E393-4C1E-85EF-FD16C73F26C2 Q37524412-C995C4CD-1785-49B8-BDFF-566D64492517 Q37707110-51D0C235-D746-4EA2-8BF0-A50D71EA3753 Q37737611-4A760C68-9B35-4E9A-B186-2DE517F6E733 Q37744742-3F5DF345-3780-4DD9-A936-A50D7B78EF63 Q37792060-6EC58418-8977-4898-AEC9-226AC873F056 Q37826274-5052528F-0B4C-4E47-A67A-4A11F5A5C24E Q37876194-5EE9C085-5947-4391-A26A-2E1996F4388F Q37913983-BFCBD837-21AB-4A62-AA75-B13290AAD160 Q37962596-4CCE3DBA-6957-41A8-8BC2-2C05B154470D Q38044064-DAA6E326-3C10-43B3-8746-1194B53D4D48

P2860

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and Un

Item

http://www.wikidata.org/entity/Q34048411

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Vorinostat in advanced prostat ...... inical Trial Consortium and Un

@ast

Vorinostat in advanced prostat ...... inical Trial Consortium and Un

@en

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy

@nl

type

Item

label

Vorinostat in advanced prostat ...... inical Trial Consortium and Un

@ast

Vorinostat in advanced prostat ...... inical Trial Consortium and Un

@en

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy

@nl

prefLabel

Vorinostat in advanced prostat ...... inical Trial Consortium and Un

@ast

Vorinostat in advanced prostat ...... inical Trial Consortium and Un

@en

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy

@nl

P1476

Vorinostat in advanced prostat ...... of Chicago Phase 2 Consortium

@en

P2093

Deborah Bradley

http://www.w3.org/2001/XMLSchema#string

Glenn Liu

http://www.w3.org/2001/XMLSchema#string

Howard Scher

http://www.w3.org/2001/XMLSchema#string

James Zwiebel

http://www.w3.org/2001/XMLSchema#string

Maha Hussain

http://www.w3.org/2001/XMLSchema#string

Roberto Pili

http://www.w3.org/2001/XMLSchema#string

Rodney Dunn

http://www.w3.org/2001/XMLSchema#string

Walter M Stadler

http://www.w3.org/2001/XMLSchema#string

P2860

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells.

Depsipeptide (FK228) inhibits growth of human prostate cancer cells.

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

P304

5541-5549

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.24597

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

David C. Smith

Dana E Rathkopf

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26771402

http://www.w3.org/2001/XMLSchema#string

P698

19711464

http://www.w3.org/2001/XMLSchema#string

P921

chemotherapy

P932

2917101

http://www.w3.org/2001/XMLSchema#string

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and Un

about

P2860

P2860

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and Un

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932